Resignation of Ms. Pooja Pandey (CFO and KMP).

Cfo ResignedKmp ResignedManagement Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Next day

₹20.60

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+5.5% vs market

Pharmaceuticals peers, median of 155sector+0.5%+4.3% vs sector

By the next day the stock moved 5.5 pts more than Nifty Microcap 250 and 4.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—-0.7—-0.0—

Next day

+4.9-0.6+5.5+0.5+4.3

+8.2-2.5+10.8-1.2+9.4

+11.6-4.2+15.8-2.4+14.0

+10.6-5.1+15.7-3.3+13.9

+15.8-4.7+20.5-3.7+19.5

+9.5-5.1+14.6-3.9+13.4

15d

-2.1-8.6+6.5-8.4+6.2

-10.1-5.2-5.0-5.9-4.3

-1.6-10.5+8.9-9.3+7.7

-2.9-12.0+9.1-11.7+8.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ms. Pooja Pandey has resigned from the position of Chief Financial Officer and Key Managerial Personnel of Brawn Biotech Ltd, effective from the close of business hours on January 5, 2026. The reason cited is personal circumstances, specifically pre-occupation and unavoidable personal matters. She confirmed there are no other material reasons behind her resignation. The company has disclosed this change under SEBI Listing Regulations and attached her resignation letter as Annexure II. No replacement or new CFO appointment has been announced in this filing.

Likely market impact

The sudden exit of the CFO, without an immediate replacement announced, could create short-term uncertainty around financial reporting and compliance oversight at Brawn Biotech. Retail investors should watch for the company's next update on the appointment of a new CFO, as a prolonged vacancy at this position may be a minor governance concern for a small-cap biotech firm.